Skip to main content
SpringerLink
Log in

Ingenol mebutate gel: a guide to its use in actinic keratosis in the EU

  • ADIS DRUG CLINICAL Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Ingenol mebutate gel (Picato®) is indicated for the topical treatment of actinic keratosis. Field-directed therapy with topical ingenol mebutate (150 µg/g gel applied once daily for 3 consecutive days for actinic keratoses on the face or scalp, and 500 µg/g gel applied once daily for 2 consecutive days for actinic keratoses on the trunk or extremities) resulted in significantly higher complete and partial clearance rates at day 57 than treatment with vehicle gel. Clearance was generally sustained during 1-year follow-up. Moreover, relative to cryosurgery alone, a 3-day course of ingenol mebutate 150 µg/g gel applied to the face and scalp 3 weeks after cryosurgery improved clearance of actinic keratosis at 11 weeks. Transient local skin responses are very common after initiation of ingenol mebutate gel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosen T, Lebowohl MG. Prevalence and awareness of actinic keratosis: barriers and opportunities. J Am Acad Dermatol. 2013;68(1 Suppl 1):S2–9.

    Article  PubMed  Google Scholar 

  2. Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S28–38.

    Article  PubMed  Google Scholar 

  3. Uhlenhake EE. Optimal treatment of actinic keratoses. Clin Interv Aging. 2013;8:29–35.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Del Rosso JQ. Current regimens and guideline implications for the treatment of actinic keratosis: proceedings of a clinical roundtable at the 2011 Winter Clinical Dermatology Conference. Cutis. 2011;88(Suppl 1):1–8.

    PubMed  Google Scholar 

  5. Nashan D, Meiss F, Muller M. Therapeutic strategies for actinic keratoses: a systematic review. Eur J Dermatol. 2013;23(1):14–32.

    CAS  PubMed  Google Scholar 

  6. Rigel DS, Stein Gold LS. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S20–7.

    Google Scholar 

  7. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486–93.

    Article  CAS  PubMed  Google Scholar 

  8. Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol. 2011;164(3):633–6.

    CAS  PubMed  Google Scholar 

  9. Rizk AM, Hammouda FM, El-Missiry MM, et al. Biologically active diterpene esters from Euphorbia peplus. Phytochem. 1985;24(7):1605–6.

    Article  CAS  Google Scholar 

  10. Picato® (ingenol mebutate) 150 and 50 micrograms/gram gel: summary of product characteristics. London: European Medicines Agency; 2014.

  11. Stahlhut M, Bertelsen M, Hoyer-Hansen M, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012;11(10):1181–92.

    CAS  PubMed  Google Scholar 

  12. Ogbourne S, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833–9.

    Article  CAS  PubMed  Google Scholar 

  13. Challacombe JM, Suhrbier A, Parsons PG, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006;177(11):8123–32.

    CAS  PubMed  Google Scholar 

  14. Hampson P, Kavanagh D, Smith E, et al. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-d dependent manner. Cancer Immunol Immunother. 2012;57(8):1241–51.

    Article  Google Scholar 

  15. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9.

    Article  CAS  PubMed  Google Scholar 

  16. Berman B, Marmur E, Larsson T, et al. Three-day topical treatment with ingenol mebutate gel 0.015% for actinic keratoses on the face and scalp: analysis of data pooled from two trials [poster no. 5623]. In: 70th Annual Meeting of the American Academy of Dermatology; 16–20 Mar 2012; San Diego.

  17. Anderson LL, Schmieder GJ, Xu Z, et al. Two-day topical treatment with ingenol mebutate gel 0.05% for actinic keratoses on the trunk and extremities: analysis of data pooled from two trials [poster no. 5640]. In: 70th Annual Meeting of the American Academy of Dermatology; 16–20 Mar 2012; San Diego.

  18. Lebwohl M, Shumack S, Stein Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratosis. JAMA Dermatol. 2013;149(6):666–70.

    Google Scholar 

  19. Berman B, Goldenberg G, Hanke W, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol. 2014;13(2):154–60.

    CAS  PubMed  Google Scholar 

  20. Leo Pharma. FIELD study 1 now complete: evaluating one year treatment outcomes of actinic keratosis after a combined lesion- and field-directed treatment approach with cryosurgery and ingenol mebutate gel [media release]. 26 Sep 2013. http://www.leo-pharma.com/Home/LEO-Pharma/Media-Centre/News/News-2013/LEO-Pharma-completes-FIELD-Study-1.aspx.

  21. Stockfleth E, et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis [poster no.IST13-1460]. In: 22nd Congress of the European Academy of Dermatology and Venereology; 2–6 Oct 2013; Istanbul.

  22. Augustin M, et al. Effect of ingenol mebutate gel on treatment satisfaction and quality of life in actinic keratosis [poster no.IST13-1530]. In: 22nd Congress of the European Academy of Dermatology and Venereology; 2–6 Oct 2013; Istanbul.

Download references

Acknowledgments

The manuscript was reviewed by: S. Saluja, Consultant in Internal Medicine, Saran Ashram, Agra, India; W.P. Werschler, Department of Medicine/Dermatology, University of Washington School of Medicine, Seattle, Washington, USA.

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson & Gillian M. Keating

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A., Keating, G.M. Ingenol mebutate gel: a guide to its use in actinic keratosis in the EU. Drugs Ther Perspect 30, 155–160 (2014). https://doi.org/10.1007/s40267-014-0121-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-014-0121-9

Keywords

Search

Navigation